Barrett's Esophagus: Ablation vs Watch-and-Wait

Research-informed explainer — last updated April 12, 2026

If your doctor found Barrett's esophagus on your scope, you likely left with two questions: how dangerous is this, and do I need a procedure to fix it? The answer to both depends almost entirely on one thing — whether your Barrett's has dysplasia, and if so, what grade. For most people with non-dysplastic Barrett's, surveillance every few years is the current standard. For those with high-grade dysplasia, ablation is clearly the better path. The middle ground — low-grade dysplasia — is where the decision gets more nuanced.

Barrett's esophagus is a condition in which the normal lining of the lower esophagus is replaced by a different type of tissue, usually because years of acid reflux have repeatedly damaged and healed the area. It affects an estimated 1 to 2 percent of the adult population and is the only known precursor to esophageal adenocarcinoma, a cancer with rising incidence over recent decades [1].

This explainer draws on peer-reviewed research from five specialists in the Convene directory. Gary Falk at the University of Pennsylvania led development of both the 2015 and 2022 American College of Gastroenterology guidelines for Barrett's, which define the current standards for who needs treatment and who can wait. Kenneth J. Chang at Hoag and UC Irvine is a co-investigator on the landmark radiofrequency ablation (RFA) trial published in the New England Journal of Medicine that established ablation as the standard for dysplastic Barrett's. Nicholas Shaheen at UNC authored the foundational AGA technical review quantifying the actual cancer risk in non-dysplastic Barrett's. Stuart Spechler and Rhonda Souza at Baylor have published extensively on the pathophysiology of Barrett's — the mechanism by which reflux leads to metaplasia and eventually dysplasia, and why acid control alone is not sufficient once dysplasia is present.

What Barrett's esophagus actually is

Normally, the lower esophagus is lined with squamous cells — the same type that line the inside of your mouth. In Barrett's, these cells are replaced by columnar cells resembling those found in the intestine, a change called intestinal metaplasia. This transformation happens gradually, driven by chronic acid and bile exposure from gastroesophageal reflux disease [8].

Barrett's itself does not cause symptoms. Your reflux symptoms may actually improve once Barrett's develops, which can give a false sense of reassurance. The concern is that Barrett's can, in some patients, progress through a sequence: non-dysplastic Barrett's to low-grade dysplasia to high-grade dysplasia to cancer. Understanding where you are in that sequence determines everything about how your care is managed.

What's the difference between ablation and watch-and-wait?

Ablation — most commonly radiofrequency ablation (RFA) — destroys the abnormal Barrett's lining using carefully controlled heat delivered through an endoscope. Over several sessions, the Barrett's tissue is eliminated and replaced by normal squamous epithelium. It is an outpatient procedure with modest recovery time but requires multiple treatment sessions and follow-up surveillance endoscopies.

Watch-and-wait (called endoscopic surveillance) means undergoing periodic upper endoscopies to sample the Barrett's tissue and look for any change toward dysplasia. No treatment is performed unless or until the biopsies show a meaningful change. The surveillance interval depends on the extent and grade of your Barrett's.

At a glance

When surveillance alone makes sense

If your Barrett's has no dysplasia, the risk of progression to cancer is low — substantially lower than early studies suggested. Nicholas Shaheen's AGA technical review, which analyzed over 200 studies, was among the first to quantify this rigorously. A key finding: early reports of Barrett's cancer risk were influenced by publication bias, with high-risk cases more likely to be reported in the literature, inflating population-level estimates [7].

Population-based studies now suggest the annual cancer risk in non-dysplastic Barrett's is roughly 0.2 to 0.5 percent per year — meaning most people with non-dysplastic Barrett's will never develop esophageal cancer. The 2022 ACG guideline by Gary Falk and colleagues reflects this data shift: patients with non-dysplastic Barrett's should undergo endoscopic surveillance every three to five years, rather than annually or more frequently [1]. Watching and waiting is not neglect — it is the guideline-supported approach for low-risk patients.

When ablation is the right choice

The 2009 NEJM trial that established radiofrequency ablation as standard care enrolled 127 patients with low-grade or high-grade dysplastic Barrett's and randomized them to RFA or sham procedure. In the RFA group, 81 percent achieved complete eradication of dysplasia and 77 percent achieved complete eradication of intestinal metaplasia [4]. In the sham group, progression to more advanced disease occurred at a rate of 19 percent. The benefit was clear and durable.

A follow-up durability study found that 98 percent of patients with complete eradication at one year remained cancer-free at three years, and complete remission was maintained in 91 percent [5]. When high-grade dysplasia is present, ablation is now standard care across American and European guidelines. For confirmed low-grade dysplasia, the 2022 ACG guideline endorses ablation as the preferred approach — though it notes that a confirmed second opinion on the pathology is recommended before treating, because low-grade dysplasia can be difficult to distinguish from non-dysplastic tissue even for experienced pathologists [1].

What research shows about progression risk

Stuart Spechler's 1986 seminal paper in the New England Journal of Medicine described Barrett's esophagus as a clinically significant precancerous condition and established the framework for modern surveillance [8]. What that early work began, decades of population studies have refined: the GERD-metaplasia-dysplasia-carcinoma sequence is real, but it moves slowly in most people and sometimes not at all.

Rhonda Souza and colleagues have shown that reflux causes esophageal injury through cytokine-mediated mechanisms — meaning the damage is more complex than simple acid burning — which explains why proton pump inhibitors alone are insufficient to reverse established Barrett's [10]. The tissue change itself is the problem, not just the ongoing reflux. This is part of why ablation has a role: removing the changed tissue removes the substrate on which dysplasia can develop.

The long-term outcome data from Stuart Spechler's trial of medical versus surgical GERD therapy — a 10-year follow-up study — showed that neither acid suppression medications nor antireflux surgery reliably eliminated Barrett's or prevented its progression [9]. This finding reinforced the need for a tissue-based intervention once dysplasia is confirmed.

What is changing in how Barrett's is managed

Screening for Barrett's has historically required endoscopy — an invasive procedure with a preparation requirement. The 2022 ACG guideline now endorses non-endoscopic screening methods such as the Cytosponge, a swallowed capsule that collects esophageal cells, as acceptable alternatives for initial screening in appropriate patients [1]. This does not change the management once Barrett's is diagnosed, but it may allow more people to be identified before dysplasia develops.

Artificial intelligence tools are also entering endoscopy practice, helping gastroenterologists identify areas of concern during Barrett's surveillance scopes that might otherwise be missed. The integration of these tools into routine surveillance is active and ongoing.

Questions to ask your doctor

• What grade is my Barrett's, and has a second pathologist confirmed that reading — especially for low-grade dysplasia?
• Based on the extent and grade, how often should I be having surveillance endoscopies?
• If I have dysplasia, am I a good candidate for radiofrequency ablation or another endoscopic treatment?
• After ablation, what is my follow-up schedule, and what does surveillance look for after treatment?
• Do I need to be on a proton pump inhibitor long-term, and will that affect my Barrett's progression risk?
• Are there any clinical trials I should know about for my stage of Barrett's?

The bottom line

Barrett's esophagus is not a single condition — it is a spectrum. For the majority of patients with non-dysplastic Barrett's, careful surveillance every three to five years is both evidence-based and safe; the cancer risk is low and the justification for immediate intervention is not there. For patients with confirmed high-grade dysplasia, radiofrequency ablation is the standard of care, with strong trial evidence showing it eradicates dysplasia and reduces cancer risk. Low-grade dysplasia sits in the middle: the current guideline recommends ablation after pathologic confirmation, but the decision benefits from a thorough conversation with a gastroenterologist who specializes in esophageal disease.